TruNativ Raises $30M Series B for Nutrition Brand Expansion

TruNativ, a rapidly growing direct-to-consumer nutrition brand, has successfully closed a $30 million Series B funding round. The significant capital infusion was spearheaded by OrbiMed, a prominent investment firm with a dedicated focus on the healthcare sector. This latest funding marks a substantial endorsement of TruNativ's innovative approach to everyday nutrition and its impressive trajectory since its inception in 2019.

Founded by the entrepreneurial duo Mamta Malhotra and Pranav Malhotra, alongside Eeshaan Merchant, TruNativ has carved a niche by offering essential nutritional products designed for household consumption. Their product portfolio currently includes protein supplements for cooking, convenient water-soluble fiber sachets, and collagen-based wellness aids. The company's strategic vision extends to further product diversification, with plans to introduce a new line of vitamin-based supplements, catering to an evolving consumer demand for comprehensive health solutions.

The financial performance of TruNativ underscores its market penetration and product appeal. For the fiscal year 2026, the company reported revenues reaching approximately ₹130 Crore, a remarkable 350% surge from the ₹37 Crore recorded in fiscal year 2025. This explosive growth is further validated by the brand's operational efficiency, processing between 7 to 10 lakh orders monthly, and a robust 45% repeat purchase rate, signaling strong customer loyalty and product satisfaction.

With this new capital, TruNativ is set to embark on an aggressive expansion strategy. A key focus will be broadening its physical retail presence across Tier I and Tier II cities, making its products more accessible to a wider consumer base. Concurrently, the company aims to forge strategic partnerships within the HORECA (hotel, restaurant, and catering) industry, integrating its nutritional offerings into the food service sector. Furthermore, the establishment of “The Good Lab”, an advanced R&D innovation center in Mumbai, will bolster its capabilities in developing next-generation nutritional products.

Beyond direct sales, TruNativ is also extending its expertise through its “Mark of Good” initiative. This program empowers other businesses to enhance their own product lines by incorporating TruNativ's scientifically formulated nutritional solutions. This B2B strategy diversifies revenue streams and amplifies the brand's impact across the broader consumer goods market. The funding round also saw participation from existing investors, including 100Unicorns, Rainmatter, and Venture Catalysts, who participated in secondary transactions. Notably, FMCG conglomerate Emami adjusted its holdings, reducing its stake from 19% to 10%.

The Series B funding round is a critical inflection point for TruNativ, providing the necessary resources to scale its operations, deepen its product innovation pipeline, and solidify its market position. The company's success highlights the growing consumer interest in health and wellness, particularly within the Indian market, which is projected to see continued expansion in the nutraceuticals and functional foods segments. This strategic move into offline channels and enhanced R&D capabilities positions TruNativ for sustained growth and leadership in the competitive nutrition sector.